Jacobs Levy Equity Management’s iRadimed IRMD Stock Holding History

Jacobs Levy Equity Management’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$752K	Sell	7,872 -812	-9%	-$74K	﹤0.01%	759
2026 Q1	$836K	Hold	8,684	–	–	﹤0.01%	744
2025 Q4	$845K	Sell	8,684 -362	-4%	-$31.1K	﹤0.01%	715
2025 Q3	$644K	Sell	9,046 -198	-2%	-$13.2K	﹤0.01%	785
2025 Q2	$553K	Sell	9,244 -13,963	-60%	-$765K	﹤0.01%	869
2025 Q1	$1.22M	Buy	23,207 +123	+0.5%	+$6.91K	﹤0.01%	774
2024 Q4	$1.27M	Sell	23,084 -1,695	-7%	-$89.2K	﹤0.01%	680
2024 Q3	$1.25M	Buy	24,779 +472	+2%	+$21.8K	﹤0.01%	687
2024 Q2	$1.07M	Buy	24,307 +11,410	+88%	+$485K	﹤0.01%	724
2024 Q1	$567K	Sell	12,897 -42	-0.3%	-$1.86K	﹤0.01%	806
2023 Q4	$614K	Sell	12,939 -128	-1%	-$5.38K	﹤0.01%	801
2023 Q3	$580K	Sell	13,067 -1	-0%	-$46	﹤0.01%	772
2023 Q2	$624K	Buy	+13,068	New	+$589K	﹤0.01%	782
2019 Q2	–	Sell	-13,188	Closed	-$370K	–	984
2019 Q1	$370K	Buy	13,188 +4,780	+57%	+$125K	0.01%	817
2018 Q4	$206K	Buy	+8,408	New	+$226K	﹤0.01%	874

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management's IRMD Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its iRadimed (IRMD) stake by 9.4% in Q2 2026, selling an estimated $74K and leaving 7,872 shares worth $752K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Jacobs Levy Equity Management first reported a position in IRMD in Q4 2018 and has held it in 15 quarters since. The position peaked at $1.27M in Q4 2024. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

Jacobs Levy Equity Management held 7,872 shares of iRadimed worth $752K as of Q2 2026.
Jacobs Levy Equity Management sold 812 iRadimed shares in Q2 2026, an estimated $74K.
iRadimed made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #759 holding.
Jacobs Levy Equity Management first reported a position in iRadimed in Q4 2018 and has held it in 15 quarters since.
Jacobs Levy Equity Management's iRadimed position peaked at $1.27M in Q4 2024.
214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.